Safety and effectiveness of topiramate for the management of painful diabetic peripheral neuropathy in an open-label extension study

Although 39.5% of subjects discontinued, most often due to AEs, the results of this 26-week, open-label extension study with topiramate (up to 600 mg/d) in subjects with moderately to severely painful DPN suggest that pain relief was effective and durable.